mTOR kinase inhibition reduces tissue factor expression and growth of pancreatic neuroendocrine tumors

ConclusionsTF isoforms are expressed in pNET. Sapanisertib suppresses TF mRNA and protein expression as well as TF co ‐factor activityin vitro andin vivo. Thus, further studies are warranted to evaluate the clinical utility of TF ‐suppressing mTORC1/2 inhibitor sapanisertib in pNET management.This article is protected by copyright. All rights reserved.

Source: Journal of Thrombosis and Haemostasis - November 25, 2018 Category: Hematology Authors: Clayton S Lewis, Hala Elnakat Thomas, Melissa Orr ‐Asman, Lisa C Green, Rachel E Boody, Kateryna Matiash, Aniruddha Karve, Yohei M. Hisada, Harold W Davis, Xiaoyang Qi, Carol Mercer, Fred V Lucas, Bruce J. Aronow, Nigel Mackman, Henri H Ve Tags: Original Article ‐ Coagulation Source Type: research